Minnesota Multidisciplinary Vasculitis Program
The Minnesota Multidisciplinary Vasculitis Program (M2VP) enrolls the 200th adult patient and 1st pediatric patient into the registry!
October 2021

Front Row L to R: S. Thaker, S. Reule, M. Rheault, H. Boyer, C. Fanola, D. Pearson, H. Muster
Back Row L to R: P. Nachman, S. Rajala, L. Ghazi, M. Beard, P. Fazeli, K. Woerner, D. Mueller, M. Pritzker, P. Ardnt
Mission
To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to Phase 2 clinical trials in ANCA Vasculitis and Systemic Lupus Erythematosus.
Covered Diseases
- Systemic vasculitis:
- Small Vessel Vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
- Medium Vessel vasculitis
- Large Vessel vasculitis
- Systemic Lupus Erythematosus
Goals
- Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with complex systemic diseases.
Multidisciplinary Team
Cardiology
Dermatology
Nephrology
- Shanthi Balani, MD
- Milind Junghare, MD
- Patrick Nachman, MD
- Michelle Rheault, MD (Pediatrics)
- Surabhi Thakar, MD
- Katti Woerner, DO
Otolaryngology (ENT)
Pulmonary
Rheumatology
- Mohanad Elfishawi, MBBCh, MS
- Parastoo Fazeli, MD
- Jacob Ijdo, PD, PhD
- Sahar Lotfi-Emran, MD, PhD
- Marta Michalska-Smith, MD
- Jerry Molitor, MD
- Luke Monteagudo, MD
- Daniel Mueller, MD
- Erik Peterson, MD
Clinical & Translational Research Team
- Tina Weiss, RN, BSN, PHN, Vasculitis & Lupus Program Nurse Navigator
- Amy Hanson, CCRC, Clinical Research Coordinator, Pediatrics
- Anael Kuperwajs Cohen, CCRC, Clinical Research Coordinator, Pediatrics
- Scott Rajala, CCRP, Clinical Research Coordinator
Ongoing Clinical Trials
ANCA Vasculitis
New Study Starting Soon!
Anti-GBM
A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)
Principal Investigator
Patrick Nachman, MD
Co-Investigators
Andrew Johnson, MD
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Aahd Kubbara, MD
Katie Pendleton, MD
Sami Safadi, MD
Study Coordinator
Nicolas Rauwolf | [email protected]
Systemic Lupus Erythematosus (SLE)
A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Principal Investigator
Parastoo Fazeli, MD
Co-Investigators
Jerry Molitor, MD, PhD
Patrick H. Nachman, MD
Marta Michalska Smith, MD
Study Coordinator:
Michelle Snyder, RN | [email protected]
A Phase 1/2, Open-label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Systemic Lupus Erythematosus
Principal Investigator
Patrick H. Nachman, MD
Co-Investigators
Parastoo Fazeli, MD
Marie Hu, MD
Nattawat Klomjit, MD
Study Coordinator:
Victoria Quinones, RN | [email protected]